SGLT2 inhibitors × glycemic control

TrialDiabetes, obesity & metabolism2021

Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.

Ildiko Lingvay et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 8,246 people · 2021

Randomised comparison

Lowered glycemic control

−0.58percentage points−0.71 to −0.44

As reported

difference −0.58 %, 95% CI −0.71 to −0.44

One number in the abstract

the abstract, start to end

placebo (placebo-adjusted LS mean change -0.58%, 95% confidence interval [CI]

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.58−0.71 to −0.44
SGLT2 inhibitorsGlycemic control

SGLT2 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.920.92 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

6 papers cite it

2021
2022
2023
2024
2025
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 33769675